Search the Newsreel

Das prognostizieren Analysten für Redcare Pharmacy NV (ETR:RDC) nach der Veröffentlichung der Ergebnisse für das zweite Quartal

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Humacyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Humacyte (HUMA) has received a notice from Nasdaq stating that its common stock failed to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has until January 27, 2027, to regain compliance by maintaining a closing bid price of …

Vanguard Capital Management (M) discloses 13.1M Macy's shares in 13G/A filing

Vanguard Capital Management has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 13,069,479 shares of Macy's Inc common stock, which represents 4.96% of the outstanding shares. The filing indicates Vanguard has sole voting power over 2,049,268 shares and sole dispositive power over …

Macy’s Faces Class Action Over WorryNoMore Furniture Protection Plan Claim Denials

Macy’s and Tarmo LLC are facing a proposed class action lawsuit alleging that their WorryNoMore furniture protection plan unfairly denies valid claims. The lawsuit, filed by Iman Shaw, claims the online claims system is designed to steer customers toward exclusions, particularly by limiting reporting …

PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PharmaCyte Biotech Inc (PMCB), detailing its current price momentum score, support and resistance levels, and indicator and moving average assessments. It highlights that PMCB's stock price is currently trading between a resistance level of 0.71 and a …

Macy's Inc (M) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Macy's Inc (M), noting its current valuation score of 8.39 and ranking within the Diversified Retail industry. It highlights the company's P/E ratio relative to its recent high and low points. The analysis also indicates that key …

Macy's Inc (M) Institutional Confidence

Macy's Inc (M) has an institutional shareholding score of 10.00, placing it first in the Diversified Retail industry. The institutional shareholding proportion is 103.99%, an 11.84% increase quarter-over-quarter. Warren Buffett is the largest institutional shareholder with 2.61 million shares, even after a slight decrease …

PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of PharmaCyte Biotech Inc (PMCB), noting its current valuation score of 8.50, which ranks 119 out of 384 in the Biotechnology & Medical Research industry. It highlights that the company's current P/E ratio is -0.66, significantly below its …

Guardian Pharmacy Services (GRDN) Projected to Release Earnings on Thursday

Humacyte Inc (HUMA) Institutional Confidence

Humacyte Inc (HUMA) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. Institutional investors currently hold 32.47% of shares, a 29.83% increase quarter-over-quarter. While some institutions like Fresenius SE & Co KGaA hold …

Macy's (M) Suffers a Larger Drop Than the General Market: Key Insights

Macy's (M) recently experienced a 1.55% drop, trailing the general market which saw smaller declines in the S&P 500, Dow, and Nasdaq. Despite this, the stock has gained 6.79% over the past month, outperforming its sector. Analysts are optimistic, anticipating an EPS of $0.35 …

PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary

PharmaCyte Biotech, Inc. reported fiscal 2026 results in its 10-K, showing zero revenue and a net loss of ($23.21M), a significant decline from the prior year's net income. The company reported a diluted loss per share of ($2.77) for 2026. Key business highlights include …

Redcare Pharmacy NV (SHPPF) (Q2 2026) Earnings Call Highlights: Revenue Growth Guidance Raised ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Redcare Pharmacy NV (SHPPF) increased its 2026 revenue growth guidance to 15% to 17%, up …

M|Macy's Inc|Price:24.678|Chg%:-0.082

This article provides a comprehensive stock analysis of Macy's Inc (M) by TradingKey, highlighting its healthy fundamentals, high growth potential, and fair valuation within the Diversified Retail industry. While institutional ownership is high and the stock is expected to trend up in the medium …

Guardian Pharmacy Services Inc (GRDN) Cash Flow

This article provides a detailed cash flow statement for Guardian Pharmacy Services Inc (GRDN), covering quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining key cash flow metrics like operating cash flow, investing cash flow, financing …

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) stock recently closed down 6.44% at $0.63, underperforming the S&P 500. The company's stock has also fallen by 15.62% over the past month, trailing its sector. Investors are looking forward to its upcoming earnings report, with projections of a 58.33% increase …

GRDN|Guardian Pharmacy Services Inc|Price:41.000|Chg%:-0.860

TradingKey provides a comprehensive stock analysis of Guardian Pharmacy Services Inc (GRDN), indicating strong fundamentals, high growth potential, and a "Strong Buy" analyst rating with a target price of $47.00. The company's valuation is considered fairly valued within the Food & Drug Retailing industry, …

ROUNDUP: Online-Apotheke Redcare legt stärker zu als erwartet - Prognose steht - 29.07.26 - News

Guardian Pharmacy Services Inc (GRDN) Institutional Confidence

Guardian Pharmacy Services Inc (GRDN) has an institutional shareholding score of 3.00, placing it 15th out of 29 in the Food & Drug Retailing industry. The institutional shareholding proportion recently saw a quarter-over-quarter decrease of 17.27%, now standing at 49.32%. James Simons is noted …

Redcare Pharmacy Aktie: Zehnjahreshoch bei der Marge

Hidden by billboards for over 100 years, the tiny holdout building in the middle of Macy’s is back in view

A five-story holdout building at 34th Street and Sixth Avenue, which prevented Macy's from fully owning a Herald Square corner, is now visible after its billboards were dismantled. This structure has been hidden by Macy's advertisements for over a century due to a historical …

Humacyte Inc Lobbyists, 2024

This OpenSecrets.org page details the lobbying activities of Humacyte Inc for 2024, identifying seven lobbyists, three of whom are "revolving door" lobbyists with previous federal government experience. The company spent $100,000 on lobbying in 2024, with G2G Consulting employing six lobbyists and DLA Piper …

Humacyte, Inc. Revenue Breakdown – NASDAQ:HUMAW

Humacyte, Inc. (NASDAQ:HUMAW) generated $2.04 million in revenue last year, primarily from its Acellular Human Tissues segment. This represents an increase from $1.56 million in the previous year. The United States was the primary source of this revenue, accounting for the entire $2.04 million.

Pedestrians walk past a Macy's store after the retailer's shopping bag sign was removed in New York City

This article features a photograph of pedestrians walking past a Macy's store in New York City after the removal of the retailer's shopping bag sign. The image was captured by Jeenah Moon on July 27, 2026. Licensing details and image specifications are also provided.

Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings

The article details the shareholder structure of Humacyte Inc (HUMA), listing major institutional shareholders and their proportional holdings. It also provides a breakdown of shareholder types and historical institutional shareholding data from Q1 2023 to Q1 2026, alongside information on related ETFs.

PharmaCyte Biotech Inc (PMCB) Cash Flow

This article provides a detailed historical cash flow statement for PharmaCyte Biotech Inc (PMCB), covering quarterly and annual data up to FY2026Q3. It includes operating, investing, and financing cash flows, along with related figures such as net income, changes in working capital, and beginning/ending …

PharmaCyte Biotech Inc (PMCB) Institutional Confidence

PharmaCyte Biotech Inc (PMCB) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 132.81% quarter-over-quarter to 9.99%. While James Simons is listed as the largest institutional …

PMCB|PharmaCyte Biotech Inc|Price:0.586|Chg%:-0.014

TradingKey provides a comprehensive stock analysis for PharmaCyte Biotech Inc (PMCB), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership but predicts a downward trend in the medium …

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

Humacyte has announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The company plans to initiate a Phase 2a study in ten adult …

Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass

Humacyte (Nasdaq: HUMA) has received FDA acceptance for its Investigational New Drug (IND) application, paving the way for a first-in-human Phase 2a clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The study, expected to enroll ten adult …

PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of PharmaCyte Biotech Inc (PMCB), highlighting major individual and institutional holders. Key shareholders include Joshua Silverman, Citadel Advisors LLC, and HRT Financial LP. The report also breaks down shareholder types and institutional holdings quarter by quarter, showing changes …

Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery

Humacyte, Inc. announced that the US FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its Coronary Tissue Engineered Vessel (CTEV). This study will evaluate the CTEV for use in Coronary Artery Bypass Grafting (CABG) surgery. The company …

PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for PharmaCyte Biotech Inc (PMCB). It states that the company has not distributed any dividends over the past five years. The page also offers current market data including its stock price, market cap, …

Macy's Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Macy's Inc (M), an omni-channel retail company operating under the Macy's, Bloomingdale's, and Bluemercury brands. It includes financial data such as market capitalization and P/E ratio, key company information like IPO date and CEO, and a list …

HUMA|Humacyte Inc|Price:0.625|Chg%:-0.014

Humacyte Inc. (HUMA) is a biotechnology company developing universally implantable bioengineered human tissues. The company is in late-stage clinical trials for vascular applications like hemodialysis and peripheral artery disease, and also has preclinical development in other areas. Trading at $0.625, the article provides an …